Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perlegen Sciences Inc.

www.perlegen.com

Latest From Glenmark Generics Inc. USA

ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump

Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.

BioPharmaceutical United States

That’s The Way The Tablet Crumbles: Industry Protests FDA Friability Test

A split tablet’s structure is compromised by definition and shouldn’t be subjected to friability testing, drug manufacturers argue in response to an FDA draft guidance.

BioPharmaceutical Regulation

Deals Shaping the Medical Industry (06/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Deals Shaping the Medical Industry (01/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Perlegen Sciences Inc.
  • Senior Management
  • Bryan Walser, MD, CEO
    Joseph Lehnen, CFO
    David R Cox, MD, PhD, CSO
    Kevin D Cooksy, VP, Bus. Dev.
    Mark J Ostrowski, SVP, Sales
  • Contact Info
  • Perlegen Sciences Inc.
    Phone: (650) 625-4500
    2021 Stierlin Ct.
    Mountain View, CA 94943
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register